Crystal-contact engineering to obtain a crystal form of the Kelch domain of human Keap1 suitable for ligand-soaking experiments

Stefan Hörer(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Yvette Hoevels(Boehringer Ingelheim (Germany)), D.J. Reinert(Boehringer Ingelheim (Germany)), Katja Ostmann
DORA PSI (Paul Scherrer Institute)
January 1, 2013
Cited by 0

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285